140 related articles for article (PubMed ID: 8675643)
21. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy of malignant lymphomas].
Luporini G
Radiol Med; 1976; 62(7-8):553-7. PubMed ID: 95671
[TBL] [Abstract][Full Text] [Related]
23. MOPP, ABVD, or both to treat Hodgkin's disease.
Martino R; Nomdedeu J; Brunet S
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
[No Abstract] [Full Text] [Related]
24. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
25. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
26. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
[TBL] [Abstract][Full Text] [Related]
28. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
29. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
30. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
31. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease.
Ann Oncol; 2001 Sep; 12(9):1213-4. PubMed ID: 11697828
[No Abstract] [Full Text] [Related]
32. [Controversial aspects in the current treatment of Hodgkin's disease].
Vicente J
Rev Clin Esp; 1987 Feb; 180(3):158-64. PubMed ID: 2437622
[No Abstract] [Full Text] [Related]
33. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
34. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
Tsushita K; Utsumi M; Shimoyama M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
[TBL] [Abstract][Full Text] [Related]
35. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
36. Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita VT
Hosp Pract (Off Ed); 1986 Sep; 21(9):103-18. PubMed ID: 2427535
[No Abstract] [Full Text] [Related]
37. [The chemotherapeutic treatment of advanced Hodgkin's disease].
Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Hodgkin lymphoma: a 50-year perspective.
Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
[No Abstract] [Full Text] [Related]
40. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
